Predicting the emergence of drug-resistant HSV-2: new predictions
© Gershengorn et al; licensee BioMed Central Ltd. 2003
Received: 20 December 2002
Accepted: 24 March 2003
Published: 24 March 2003
Mathematical models can be used to predict the emergence and transmission of antiviral resistance. Previously it has been predicted that high usage of antivirals (in immunocompetent populations) to treat Herpes Simplex Virus type 2 (HSV-2) would only lead to fairly low levels of antiviral resistance. The HSV-2 predictions were based upon the assumption that drug-resistant strains of HSV-2 would be less infectious than drug-sensitive strains but that the drug-resistant strains would not be impaired in their ability to reactivate. Recent data suggest that some drug-resistant strains of HSV-2 are likely to be impaired in their ability to reactivate. Objectives: (1) To predict the effect of a high usage of antivirals on the prevalence of drug-resistant HSV-2 under the assumption that drug-resistant strains will be less infectious than drug-sensitive strains of HSV-2 and also have an impaired ability to reactivate. (2) To compare predictions with previous published predictions.
We generated theoretical drug-resistant HSV-2 strains that were attenuated (in comparison with drug-sensitive strains) in both infectivity and ability to reactivate. We then used a transmission model to predict the emergence and transmission of drug-resistant HSV-2 in the immunocompetent population assuming a high usage of antivirals.
Our predictions are an order of magnitude lower than previous predictions; we predict that even after 25 years of high antiviral usage only 5 out of 10,000 immunocompetent individuals will be shedding drug-resistant virus. Furthermore, after 25 years, 52 cases of HSV-2 would have been prevented for each prevalent case of drug-resistant HSV-2.
The predicted levels of drug-resistant HSV-2 for the immunocompetent population are so low that it seems unlikely that cases of drug-resistant HSV-2 will be detected.
Mathematical models can be used as health policy tools to predict the emergence and transmission of antiviral resistance [1–5]. These models have predicted, that if treatment rates are high, that high levels of antiviral resistance to HIV will arise very quickly; for example, 42% of HIV cases in San Francisco are predicted to be infected with drug-resistant strains by 2005 [3, 4]. These theoretical predictions have been compared with empirical data, and shown to be valid [4, 6]. In stark contrast to the HIV predictions, it has been predicted that high usage of antivirals to treat Herpes Simplex Virus type 2 (HSV-2) would only lead to low levels of resistance (in immunocompetent populations) [1, 2]. These predictions were based upon the assumption that drug-resistant strains of HSV-2 would be less infectious than drug-sensitive strains, but that the drug-resistant strains would not be impaired in their reactivation ability. However, recent experience with drug-resistant variants has shown that the majority of these variants are deficient in the expression of thymidine kinase [7–9], a phenotype that is known to be associated with a reduced ability to reactivate [8–10]. Here, we model the effect of impaired reactivation ability of drug-resistant strains and generate new predictions for the expected emergence of antiviral resistance to HSV-2. We also assess the beneficial and the potential detrimental epidemic-level effects of a high usage of antivirals by conducting a "biological cost-benefit" analysis and calculating the value of a treatment evaluation criterion (TEC(t)). We compare our new predictions for the expected levels of drug resistant HSV-2 and TEC(t) with previous predictions.
We used a previously published mathematical model to track the effect of a high usage of antivirals on the transmission dynamics of drug-sensitive and drug-resistant HSV-2 strains in an immunocompetent population [1, 2]. We model the effect of episodic treatment on epidemic viral dynamics; hence treatment occurs only during an infectious outbreak and reduces the length of the infectious period (which reduces the possibility of transmission of HSV-2). Thus, the greater the treatment rate (in terms of the number of infectious episodes treated) then the greater the reduction in transmission. The possibility of transmitted (i.e., primary) resistance emerging, as well as the development of both temporary and permanent acquired drug resistance are included in the model. Individuals with permanent resistance are assumed to reactivate with drug-resistant HSV-2 strains during each subsequent outbreak. Individuals with transient resistance are modeled by assuming that they only present with drug resistance during the episode in which they acquire resistance; hence, all of their subsequent infectious outbreaks are drug-sensitive. Details of the model, which is specified by a series of six ordinary differential equations, are given elsewhere [1, 2]. A web-based version of this model can be run at http://www.biomath.ucla.edu/faculty/sblower.
To generate our predictions we analyzed the model using time-dependent uncertainty analyses [1–5], [11–13]. These analyses were based upon Latin Hypercube Sampling (LHS), a sampling technique that enables us to make predictions using a range of parameter values for each parameter. Hence, each parameter is specified by a probability distribution function (pdf) rather than a single value; the pdfs that we used have been reported and discussed previously . Each pdf was randomly sampled, without replacement, 1,000 times. Predictions were generated by simulating the model 1,000 times using the parameter values sampled by LHS; methodological details are given elsewhere [1–5], [11–13]. We predicted the effect of 1,000 drug-sensitive strains of HSV-2 that each differed in their infectivity and reactivation ability. In terms of infectivity, the transmission probability of drug-sensitive strains was assumed to lie between 0.1 and 0.5 . In terms of reactivation ability, drug-sensitive strains were assumed to cause anywhere from one to 20 (with a most likely value of 12) viral shedding infectious episodes per year ; these viral shedding episodes could be either symptomatic or asymptomatic.
We then simulated the model and predicted the levels of drug resistance that would emerge, assuming that antiviral usage was high (i.e., that 10–50% of the individuals who were shedding virus at any particular time could receive episodic treatment). In order to compare with previous predictions we predicted the temporal dynamics of: (i) the prevalence of drug-resistant infectiousness and (ii) the value of the Treatment Evaluation Criterion (TEC(t)) where TEC(t) equals the average number of drug-sensitive cases prevented at time t per prevalent case of drug resistance . Thus, a value of TEC(t) of greater than one represents a net beneficial effect of antiviral usage at the epidemic level (i.e., more than one drug-sensitive case of HSV-2 is prevented for each prevalent case of drug resistance ).
Previous estimates (blue data; Figure 2B) show that even after 25 years of high antiviral usage 4.5 cases of HSV-2 would be prevented for each prevalent case of drug-resistant HSV-2. Our new results (red data) show that if the drug-resistant strains are attenuated in both their ability to infect and reactivate then the value of TEC would be even greater; after 25 years 52 cases of HSV-2 would be prevented for each prevalent case of drug-resistant HSV-2.
Here we have predicted the emergence and transmission of antiviral resistance in the immunocompetent population (i.e., the "general population"). More complex models could be developed to assess the emergence and transmission of drug-resistant HSV-2 strains in a population that contains both immunocompetent and immunocompromised individuals. Acquired resistance occurs with a much greater probability in immunocompromised individuals (in comparison with imunocompetent individuals) due to a variety of host, virological and treatment factors ; hence the prevalence of resistant HSV-2 in samples of immunocompromised individuals has already been reported to be 4–7% . It is unlikely that drug-resistant HSV-2 cases in immunocompromised individuals will lead to significant increases in drug resistance in the immunocompetent population unless very transmissible strains of drug-resistant HSV-2 arise and considerable sexual mixing occurs between immunocompromised and immunocompetent individuals.
Mathematical models can be very useful in predicting the spread of antiviral resistance [1, 4, 15]. We have shown previously [1, 2] that a substantial increase in antiviral usage in immunocompetent populations would have a substantial beneficial impact on herpes epidemics in terms of preventing new infections, and have a negligible detrimental impact in terms of generating drug resistance (i.e., TEC(t) >> 1). Our new predictions for the emergence of drug resistant HSV-2 (where we have included the assumption that drug resistant strains of HSV-2 will have an impaired ability to reactivate) are an order of magnitude lower than previous predictions. Our results suggest that the very low levels of drug-resistant HSV-2 that have been observed sofar in the "real-world" in the immunocompetent population [8, 14] are not unexpected, and also are not likely to increase. Given the low levels of drug resistance that are to be expected (5 per 10,000 immunocompetent individuals) it seems unlikely that cases of drug-resistant HSV-2 that arise in the immunocompetent population will be detected unless extremely large-scale surveillance systems are put in place.
We thank the National Institute of Allergy & Infectious Diseases (Grant #: R01-AI41935 to SMB), and the Centers for Disease Control (Grant #: R18/CCR915950 to SMB) for financial support.
- Blower SM, Porco TC, Darby G: Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nature Medicine. 1998, 4: 673-678. 10.1038/3210.View ArticlePubMedGoogle Scholar
- Gershengorn HB, Blower SM: The impact of antivirals & the emergence of drug resistance: HSV-2 epidemic control. AIDS Patient Care & STDs. 2000, 14 (3): 133-142. 10.1089/108729100317911.View ArticleGoogle Scholar
- Blower SM, Gershengorn H, Grant R: A Tale of Two Futures: HIV and antiretroviral therapy in San Francisco. Science. 2000, 287: 650-654. 10.1126/science.287.5453.650.View ArticlePubMedGoogle Scholar
- Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO: Predicting the unpredictable: transmission of drug-resistant HIV. Nature Medicine. 2001, 7 (9): 1016-1020. 10.1038/nm0901-1016.View ArticlePubMedGoogle Scholar
- Velasco-Hernandez JX, Gershengorn HB, Blower SM: Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?. The Lancet Infectious Diseases. 2002, 2 (8): 487-493. 10.1016/S1473-3099(02)00346-8.View ArticlePubMedGoogle Scholar
- Blower SM, Aschenbach AN, Kahn JO: Predicting the transmission of drug-resistant HIV: comparing theory and data. The Lancet Infectious Diseases. 2003, 3 (1): 10-11. 10.1016/S1473-3099(03)00479-1.View ArticlePubMedGoogle Scholar
- Collins P, Darby G: Laboratory studies of herpes simplex virus strains resistant to acyclovir. Reviews in Medical Virology. 1991, 1: 19-28.View ArticleGoogle Scholar
- Field HJ: Herpes simplex virus antiviral drug resistance – current trends and future prospects. Journal of Clinical Virology. 2001, 21: 261-269. 10.1016/S1386-6532(00)00169-4.View ArticlePubMedGoogle Scholar
- Morfin F, Thouvenot D: Herpes simplex virus resistance to antiviral drugs. Journal of Clinical Virology. 2003, 26 (1): 29-37. 10.1016/S1386-6532(02)00263-9.View ArticlePubMedGoogle Scholar
- Efstathiou S, Kemp S, Darby G, Minson AC: The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. Journal of General Virology. 1989, 70: 869-879.View ArticlePubMedGoogle Scholar
- Blower SM, Dowlatabadi H: Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. International Statistics Review. 1994, 2: 229-243.View ArticleGoogle Scholar
- Blower SM, McLean AR, Porco T, Sanchez M, Small PM, Hopewell P, Moss A: The intrinsic transmission dynamics of tuberculosis epidemics. Nature Medicine. 1995, 1 (8): 815-821.View ArticlePubMedGoogle Scholar
- Lietman T, Porco TC, Dawson C, Blower SM: Global elimination of trachoma: how frequently should we administer mass chemotherapy?. Nature Medicine. 1999, 5: 572-576. 10.1038/8451.View ArticlePubMedGoogle Scholar
- Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D: Herpes simplex virus resistance to acyclovir and peniciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003, 16 (1): 114-28. 10.1128/CMR.16.1.114-128.2003.View ArticlePubMedPubMed CentralGoogle Scholar
- Blower SM, Volberding P: What can modeling tell us about the threat of antiviral drug resistance?. Current Opinion in Infectious Diseases. 2002, 15 (6): 609-614.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/3/1/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.